Journal
CURRENT HIV/AIDS REPORTS
Volume 14, Issue 2, Pages 47-53Publisher
SPRINGER
DOI: 10.1007/s11904-017-0351-2
Keywords
Liver fibrosis; Nash; NAFLD; HIV
Categories
Funding
- DZIF TTU HIV Project [05.803]
- German Center for Infection Research (DZIF)
Ask authors/readers for more resources
Abnormal liver enzymes (LE) are common in patients infected with the human immunodeficiency virus (HIV) even in the absence of viral hepatitis or alcohol abuse. With availability of antiretroviral combination therapy, life expectancy has improved dramatically and as a consequence the spectrum of liver disease is changing. Increased reports on the development of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) in HIV coinfected patients raise questions around prevalence, clinical manifestations, and clinical outcome of these liver diseases in HIV coinfection. Moreover, the potential impact of combination antiretroviral therapy as well as direct HIV effects on the emergence of non-alcoholic fatty liver disease needs to be explored. This review summarizes the recent literature on NAFLD and NASH in HIV.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available